Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

NCT00060645 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors
Lymphoma
Multiple Myeloma

Interventions

DRUG: ridaforolimus

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]